bioRxiv Science⌕ Search

Biology subjects

Svetlichnyy, D.

Publications and source records attributed to Svetlichnyy, D..

2 recordsLinked to original sources

DrugForm-DTA: Towards real-world drug-target binding Affinity Model

Drug-target affinity (DTA) prediction is a fundamental problem in drug discovery. Computational methods for predicting DTA can greatly assist drug design by decreasing the search space and reducing the number of protein-ligand complexes with low affinity. Currently DTA approaches often do not require protein three-dimensional (3D) structural information, which is often not accessible. In this study we present the DrugForm-DTA model, which uses only structure-less representations of ligand and protein. It is a Transformer-based neural network with protein encoding based on ESM, and small molecule ligand encoding obtained with Chemformer. We evaluated the model on standard benchmarks Davis and KIBA, and revealed superior performance of DrugForm-DTA with best result for KIBA (MSE=0.117). Moreover, we developed a ready-to-use model using BindingDB dataset that was subjected to high-quality filtering and transformation. Overall, our method predicts drug-target affinity values with a confidence level comparable to a single in-vitro experiment. Also, we compared DrugForm-DTA against molecular modeling methods and revealed higher efficacy of the developed model for drug-target affinity predictions. Our investigation provides a high accuracy neural network model with performance comparable to experi-mental measurements, filtered and reassessed BindingDB dataset for further usage, and demonstrates outstanding applicability of the proposed method for DTA prediction. Author summaryPredicting drug-target binding affinity is a crucial task in computational drug discovery. Here we present DrugForm-DTA, a ready-to-use Transformer-based model which requires only protein amino acid sequence and ligand SMILES as inputs. The model shows excellent results at commonly used benchmarks. We believe that the success in solving machine learning tasks depends on data quality and quantity, so the main focus of our work is the training data, but not a sophisticated neural architecture. We used BindingDB database as the source of experimental affinity measurements and prepared a refined and purified dataset, suitable for training machine learning models. Trained on this dataset, the DrugForm-DTA model demonstrates accuracy, comparable to a single in-vitro experiment. We also reveal that our model outperforms molecular modeling methods in estimating binding affinity. Both the prepared dataset and the trained model is published and freely available.

bioinformatics↗

Identification Of cis-Regulatory Mutations Generating De Novo Edges In Personalized Cancer Gene Regulatory Networks

The identification of functional non-coding mutations is a key challenge in the field of genomics, where whole-genome re-sequencing can swiftly generate a set of all genomic variants in a sample, such as a tumor biopsy. The size of the human regulatory landscape places a challenge on finding recurrent cis-regulatory mutations across samples of the same cancer type. Therefore, powerful computational approaches are required to sift through the tens of thousands of non-coding variants, to identify potentially functional variants that have an impact on the gene expression profile of the sample. Here we introduce an integrative analysis pipeline, called - cisTarget, to filter, annotate and prioritize non-coding variants based on their putative effect on the underlying 'personal' gene regulatory network. We first validate -cisTarget by re-analyzing three cases of oncogenic non-coding mutations, namely the TAL1 and LMO1 enhancer mutations in T-ALL, and the TERT promoter mutation in melanoma. Next, we re-sequenced the full genome of ten cancer cell lines of six different cancer types, and used matched transcriptome data and motif discovery to infer master regulators for each sample. We identified candidate functional non-coding mutations that generate de novo binding sites for these master regulators, and that result in the up-regulation of nearby oncogenic drivers. We finally validated the predictions using tertiary data including matched epigenome data. Our approach is generally applicable to re-sequenced cancer genomes, or other genomes, when a disease- or sample-specific gene signature is available for network inference. -cisTarget is available from http://mucistarget.aertslab.org.

genomics↗